The acute effects of short-term insulin therapy on the secretory ability of beta cells in patients with diabetes mellitus type 2, after the secondary failure of the oral therapy

2020 ◽  
Author(s):  
Aleksandra Grbic ◽  
Gabrijela Malesevic ◽  
Valentina Soldat-Stankovic ◽  
Bojana Caric ◽  
Snjezana Popovic-Pejcic
Keyword(s):  
Diabetes Mellitus ◽  
Insulin Therapy ◽  
Beta Cells ◽  
Diabetes Mellitus Type 2 ◽  
Oral Therapy ◽  
Acute Effects ◽  
Short Term ◽  
Secondary Failure ◽  
Patients With Diabetes

scholarly journals Causes of the Oral therapy secondary failure in patients with Diabetes mellitus type 2

2009 ◽  
Vol 40 (1-2) ◽  
pp. 27-32
Author(s):  
Aleksandra Grbić ◽  
Ljiljana Lakić ◽  
Mirjana Bojić ◽  
Branislav Gašić
Keyword(s):  
Diabetes Mellitus ◽  
Diabetes Mellitus Type 2 ◽  
Oral Therapy ◽  
Diabetes Mellitus Type ◽  
Secondary Failure ◽  
Patients With Diabetes

scholarly journals Intensification of glucose-lowering treatment in patients with diabetes mellitus type 2 on insulin therapy: Perspectives of dapagliflozin

2016 ◽  
Vol 19 (1) ◽  
pp. 72-79
Author(s):  
Olga Yuryevna Sukhareva ◽  
Marina Vladimirovna Shestakova
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Clinical Trials ◽  
Type 2 Diabetes Mellitus ◽  
Insulin Therapy ◽  
Diabetes Mellitus Type 2 ◽  
Glucose Lowering ◽  
Patients With Diabetes ◽  
Difficult Issue

Intensification of antihyperglycaemic treatment in patients with poorly controlled type 2 diabetes mellitus who were on insulin therapy remains a difficult issue. Results from clinical trials with the sodium-glucose linked transporter (SGLT-2) inhibitor dapagliflozin as add-on therapy in patients with type 2 diabetes mellitus using insulin are summarised and discussed in the article.

Sign in / Sign up

Export Citation Format

Share Document